NCT01991210 2017-08-21A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)Genentech, Inc.Phase 2 Terminated95 enrolled